Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

By  

Oncology Research and Treatment, Vol. 35, Iss. 12, 2012-10 ,pp. : 740-745

Karger

Access to resources Recommend Favorite

Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab

By  

Oncology, Vol. 93, Iss. 1, 2017-05 ,pp. : 51-61

Karger

Access to resources Recommend Favorite

Combination Therapy of Lapatinib and Capecitabine forErbB2-Positive Metastatic or Locally Advanced BreastCancer: Results from the Lapatinib Expanded AccessProgram (LEAP) in Central and Eastern Europe

By  

Oncology Research and Treatment, Vol. 34, Iss. 5, 2011-04 ,pp. : 233-238

Karger

Access to resources Recommend Favorite

Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2++ metastatic breast cancer with letrozole alone or in combination with lapatinib

By Sherrill Beth   Sherif Bintu   Amonkar Mayur M.   Maltzman Julie   O’Rourke Lisa   Johnston Stephen  

Current Medical Research and Opinion, Vol. 27, Iss. 12, 2011-12 ,pp. : 2245-2252

Informa Healthcare

Access to resources Recommend Favorite

Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence

By Demonty Gaston  

Women's Health, Vol. 3, Iss. 5, 2007-09 ,pp. : 523-528

Future Medicine

Access to resources Recommend Favorite